Akili Interactive Labs

Akili is a digital therapeutics company which core therapeutic engine, the Selective Stimulus Management Engine (SSME), is specifically designed to target and activate neural systems involved in attentional control. This core platform has the potential to be applied across a diverse set of indications within psychiatry and neurology. Backed by robust clinical research, Akili's treatments are delivered to patients through engaging interactive mobile games, personalized to each individual and built to feel like high-end entertainment products. The SSME technology has already demonstrated proof-of-concept in controlled trials targeting attention and cognitive dysfunction in ADHD, ASD, MS, and MDD. Built on the SSME technology, Akili developed EndeavorRx, the first-ever FDA-cleared prescription video game and the first-ever FDA-cleared commercial product indicated to improve attention function in children between the ages of 8 to 12 years with primarily inattentive or combined-type ADHD.